Second Genome, Inc.

Second Genome, Inc. has been a member of Linktree for 4 years and joined in August 2021. The social media accounts linked to from Second Genome, Inc. are: • Facebook • Instagram • LinkedIn • Email • X Besides social media accounts, SecondGenome has populated their site with: • Second Genome Home Page • Culture and Careers • Press Releases • Events • Bayer Collaboration Milestone Accomplished • Arena Pharmaceuticals Collaboration Announcement • Gilead Collaboration Announcement • NASH Collaboration with VCU • DDW 2022: Discovering Immunomodulatory Microbiome-Derived Peptides with Therapeutic Potential through Multi-Technology Meta-Analysis and Functional Assays • DDW 2022: SG-5-00455 Improves Epithelial Barrier Function and Promotes Mucosal Healing in IBD • SG-3-06686 overview SITCWorkshop • Virtual KOL Panel: SG-5-00455 and the Role of Mucosal Healing and PAI-1/2 in IBD • SG-5-00455: Development Candidate Targeting PAI-1/2 for IBD Treatment • Crohn's and Colitis Congress 2022, SG-5-00455 • Second Genome Appoints Joseph Dal Porto, Ph.D., as Chief Scientific Officer • Patent granted for SG proteins for the treatment of epithelial barrier function disorders • The Future of Immunotherapy Helena Kiefel, Head of Oncology • Crohn's & Colitis Foundation's® IBD Innovate Conference • SITC 2021 Preclinical Data: SG-3-00802 Targets a Key Mechanism Required for Efficacious Immunotherapy • Cold Spring Harbor Laboratory's Genome Informatics Conference • Second Genome Presents Preclinical Data for SG-3-0020 at the 2021 AACR-NCI-EORTC International Conference on Cancer Therapeutics • A novel microbiome-derived peptide, SG-3-00802 reverses resistance to anti-PD1 therapy • Second Genome Presents Preclinical Data at ESMO 2021 • #closethecaregap • CC Personal Stories • The Power of Poop: Do Fecal Transplants Help Treat IBD? • Cell Press article